Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476893 | 0.97 | — | — | |
| SCHEMBL13082626 | 0.86 | — | — | |
| SCHEMBL1141653 | 0.83 | FGFR1 (0.32) | ABL1 | |
| SCHEMBL1141555 | 0.83 | ABL1 (0.31) | ABL1 | |
| SCHEMBL29205152 | 0.82 | ABL1 (0.30) | ABL1 | |
| SCHEMBL11913010 | 0.82 | ABL1 (0.32) | ABL1 | |
| SCHEMBL31178628 | 0.81 | CYP4F2 (0.30) | — | |
| SCHEMBL27165318 | 0.80 | ABL1 (0.30) | ABL1 | |
| SCHEMBL1141583 | 0.79 | DGAT1 (0.34) | — | |
| SCHEMBL24456174 | 0.79 | GAA (0.33) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | claimed |
| US-8354528-B2 | Process for making thienopyrimidine compounds | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | ABL1 146/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | ABL1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.